HuGE Literature Finder
Records
1
-
30
| ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. International journal of hematology 2022 7 116 (5): 659-668. Morita Yasuyoshi, Nannya Yasuhito, Ichikawa Motoshi, Hanamoto Hitoshi, Shibayama Hirohiko, Maeda Yoshinobu, Hata Tomoko, Miyamoto Toshihiro, Kawabata Hiroshi, Takeuchi Kazuto, Tanaka Hiroko, Kishimoto Junji, Miyano Satoru, Matsumura Itaru, Ogawa Seishi, Akashi Koichi, Kanakura Yuzuru, Mitani Kinu |
| Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes. Scientific reports 2022 4 12 (1): 5925. Maurya Nehakumari, Mohanty Purvi, Dhangar Somprakash, Panchal Purvi, Jijina Farah, Mathan S Leo Prince, Shanmukhaiah Chandrakala, Madkaikar Manisha, Vundinti Babu R |
| Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes. Hematological oncology 2022 11 . Lee Wan-Hsuan, Lin Chien-Chin, Wang Yu-Hung, Yao Chi-Yuan, Kuo Yuan-Yeh, Tseng Mei-Hsuan, Peng Yen-Ling, Hsu Cheng-An, Sun Hsun-I, Chuang Yi-Kuang, Hsu Chia-Lang, Tien Feng-Ming, Tsai Cheng-Hong, Chou Wen-Chien, Hou Hsin-An, Tien Hwei-Fa |
| Genetic mutations associated with blood count abnormalities in myeloid neoplasms. Hematology (Amsterdam, Netherlands) 2022 6 27 (1): 765-771. Polprasert Chantana, Kongkiatkamon Sunisa, Niparuck Pimjai, Rattanathammethee Thanawat, Wudhikarn Kitsada, Chuncharunee Suporn, Kobbuaklee Sirorat, Suksusut Amornchai, Lanamtieng Theerin, Lawasut Panisinee, Asawapanumas Thiti, Bunworasate Udomsak, Rojnuckarin Ponlap |
| Low-Risk Myelodysplastic Syndrome Revisited: Morphological, Autoimmune, and Molecular Features as Predictors of Outcome in a Single Center Experience. Frontiers in oncology 2022 4 12 795955. Fattizzo Bruno, Levati Giorgia Virginia, Giannotta Juri Alessandro, Cassanello Giulio, Cro Lilla Marcella, Zaninoni Anna, Barbieri Marzia, Croci Giorgio Alberto, Revelli Nicoletta, Barcellini Wil |
| Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA. Blood advances 2022 2 6 (10): 3178-3188. Garcia-Gisbert Nieves, Garcia-Ávila Sara, Merchán Brayan, Salido Marta, Fernández-Rodríguez Concepción, Gibert Joan, Fernández-Ibarrondo Lierni, Camacho Laura, Lafuente Marta, Longarón Raquel, Espinet Blanca, Vélez Patricia, Pujol Ramon M, Andrade-Campos Marcio, Arenillas Leonor, Salar Antonio, Calvo Xavier, Besses Carles, Bellosillo Beatr |
| New genetic variants of TET2 and ASXL1 identified by next generation sequencing and pyrosequencing in a patient with MDS-RS-MLD and secondary acute myeloid leukemia. Central-European journal of immunology 2022 2 46 (4): 524-530. Adamska Monika Ma?gorzata, Kowal-Wi?niewska Ewelina, Kiwerska Katarzyna, Ustaszewski Adam, Czerwi?ska-Rybak Joanna, Kandu?a Zuzanna, Wojtaszewska Marzena, Bara?ska Marta, Pruchniewski ?ukasz, Lewandowski Krzysztof, Jarmu?-Szymczak Ma?gorzata, Gil Lid |
| Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes. British journal of haematology 2022 6 198 (4): 713-720. Volpe Virginia O, Al Ali Najla, Chan Onyee, Padron Eric, Sallman David A, Kuykendall Andrew, Sweet Kendra, Lancet Jeffrey E, Komrokji Rami |
| Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS). Clinical lymphoma, myeloma & leukemia 2022 2 22 (7): e467-e476. Chan Onyee, Ali Najla Al, Sallman David, Padron Eric, Lancet Jeffrey, Komrokji Ra |
| Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 2021 Jun . Kanagal-Shamanna Rashmi, Montalban-Bravo Guillermo, Sasaki Koji, Darbaniyan Faezeh, Jabbour Elias, Bueso-Ramos Carlos, Wei Yue, Chien Kelly, Kadia Tapan, Ravandi Farhad, Borthakur Gautam, Soltysiak Kelly A, Routbort Mark, Patel Keyur, Pierce Sherry, Medeiros L Jeffrey, Kantarjian Hagop M, Garcia-Manero Guiller |
| Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromes. Cancer medicine 2021 Feb . Yan Xuefen, Wang Lu, Jiang Lingxu, Luo Yingwan, Lin Peipei, Yang Wenli, Ren Yanling, Ma Liya, Zhou Xinping, Mei Chen, Ye Li, Xu Gaixiang, Xu Weilai, Yang Haiyang, Lu Chenxi, Jin Jie, Tong Hongy |
| [Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome]. Zhongguo shi yan xue ye xue za zhi 2021 12 29 (6): 1864-1868. Zhao Fang, Wang Kai-Li, Qin Yu-Ting, Nilupar Tuerxun, Patiguli Abulizi, Jiang Ming, Hao Jian-Pi |
| Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype. British journal of haematology 2021 3 193 (4): 798-803. Duetz Carolien, Westers Theresia M, In 't Hout Florentien E M, Cremers Eline M P, Alhan Canan, Venniker-Punt Bianca, Visser-Wisselaar Heleen A, Chitu Dana A, de Graaf Aniek O, Smit Linda, Jansen Joop H, van de Loosdrecht Arjan |
| Have we reached a molecular era in myelodysplastic syndromes? Hematology. American Society of Hematology. Education Program 2021 12 2021 (1): 418-427. Voso Maria Teresa, Gurnari Carme |
| High erythroferrone expression in CD71 erythroid progenitors predicts superior survival in myelodysplastic syndromes. British journal of haematology 2021 1 192 (5): 879-891. Riabov Vladimir, Mossner Maximilian, Stöhr Alexandra, Jann Johann-Christoph, Streuer Alexander, Schmitt Nanni, Knaflic Antje, Nowak Verena, Weimer Nadine, Obländer Julia, Palme Iris, Schumann Christiane, Baldus Claudia D, Schulze Torsten J, Wuchter Patrick, Röhl Henning, Jawhar Ahmed, Weiss Christel, Boch Tobias, Metzgeroth Georgia, Neumann Martin, Hofmann Wolf-Karsten, Nolte Florian, Nowak Dani |
| Letter to the Editor regarding the article "Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis". Critical reviews in oncology/hematology 2021 5 162 103295. Yang Tingfang, Wang Li, Zhang Yo |
| Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. British journal of haematology 2021 7 194 (4): 708-717. Martín Iván, Villamón Eva, Abellán Rosario, Calasanz Maria José, Irigoyen Aroa, Sanz Guillermo, Such Esperanza, Mora Elvira, Gutiérrez Míriam, Collado Rosa, García-Serra Rocío, Vara Míriam, Blanco Mª Laura, Oiartzabal Itziar, Álvarez Sara, Bernal Teresa, Granada Isabel, Xicoy Blanca, Jerez Andrés, Calabuig Marisa, Diez Rosana, Gil Ángela, Díez-Campelo María, Solano Carlos, Tormo Mar, |
| The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm. International journal of laboratory hematology 2021 7 43 (6): 1501-1509. Ibrar Warda, Zhang Weiwei, Cox Jesse Lee, Cushman-Vokoun Allison, Fu Kai, Greiner Timothy C, Yuan |
| Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis. Haematologica 2021 9 107 (8): 1815-1826. Gutierrez-Rodrigues Fernanda, Beerman Isabel, Groarke Emma M, Patel Bhavisha A, Spitofsky Nina, Dillon Laura W, Raffo Diego Quinones, Hourigan Christopher S, Kajigaya Sachiko, Ferrucci Luigi, Young Neal |
| [Correlation between U2AF1 Gene Mutation Characteristics and Clinical Manifestations and Prognosis in Patients with Myelodysplastic Syndrome]. Zhongguo shi yan xue ye xue za zhi 2020 Dec 28 (6): 1977-1984. Zhao Wen-Shu, Zhang Yin-Tian, Jiang Qian-Li, Liu Qi-Fa, Dai M |
| Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes. International journal of laboratory hematology 2020 Nov . Patel Jay L, Abedi Mehrdad, Cogle Christopher R, Erba Harry P, Foucar Kathryn, Garcia-Manero Guillermo, Grinblatt David L, Komrokji Rami S, Kurtin Sandra E, Maciejewski Jaroslaw P, Pollyea Daniel A, Revicki Dennis A, Roboz Gail J, Savona Michael R, Scott Bart L, Sekeres Mikkael A, Steensma David P, Thompson Michael A, Dawn Flick Elizabeth, Kiselev Pavel, Louis Chrystal U, Nifenecker Melissa, Swern Arlene S, George Tracy |
| Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood advances 2020 May 4 (9): 1942-1949. Gardin Claude, Pautas Cécile, Fournier Elise, Itzykson Raphaël, Lemasle Emilie, Bourhis Jean-Henri, Adès Lionel, Marolleau Jean-Pierre, Malfuson Jean-Valère, Gastaud Lauris, Raffoux Emmanuel, Lambert Juliette, Braun Thorsten, Thomas Xavier, Chantepie Sylvain, Cluzeau Thomas, de Botton Stéphane, Berthon Céline, Boissel Nicolas, Duployez Nicolas, Terré Christine, Peffault de Latour Régis, Michallet Mauricette, Celli-Lebras Karine, Preudhomme Claude, Dombret Her |
| [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2020 6 41 (5): 379-386. Cai Y N, Xu Z F, Li B, Qin T J, Pan L J, Qu S Q, Hu N B, Liu D, Huang H J, Shi Z X, Zhang Y D, Xiao Z |
| Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations. Journal of clinical pathology 2020 3 73 (11): 728-736. Liu Yen-Chun, Illar Gwendolyn M, Bailey Nathanael Gl |
| Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2-mutated neoplasms. Leukemia 2020 12 35 (8): 2371-2381. Todisco Gabriele, Creignou Maria, Gallì Anna, Guglielmelli Paola, Rumi Elisa, Roncador Marco, Rizzo Ettore, Nannya Yasuhito, Pietra Daniela, Elena Chiara, Bono Elisa, Molteni Elisabetta, Rosti Vittorio, Catricalá Silvia, Sarchi Martina, Dimitriou Marios, Ungerstedt Johanna, Vannucchi Alessandro Maria, Hellström-Lindberg Eva, Ogawa Seishi, Cazzola Mario, Malcovati Lu |
| Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. Annals of hematology 2020 1 99 (3): 527-537. Martín Iván, Navarro Blanca, Serrano Alicia, Villamón Eva, Calabuig Marisa, Solano Carlos, Chaves Felipe Javier, Yagüe Nuria, Orts Maribel, Amat Paula, Fuentes Azahara, Seda Enrique, García Francisca, Hernández-Boluda Juan Carlos, Tormo M |
| Impact of mutational variant allele frequency on prognosis in myelodysplastic syndromes. American journal of cancer research 2020 10 (12): 4476-4487. Jiang Lingxu, Wang Lu, Shen Chuying, Zhu Shuanghong, Lang Wei, Luo Yingwan, Zhang Hua, Yang Wenli, Han Yueyuan, Ma Liya, Ren Yanling, Zhou Xinping, Mei Chen, Ye Li, Xu Weilai, Yang Haiyang, Lu Chenxi, Jin Jie, Tong Hongy |
| SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clinical lymphoma, myeloma & leukemia 2020 3 20 (6): 400-406.e2. Zhang Qing, Haider Mintallah, Al Ali Najla H, Lancet Jeffrey E, Epling-Burnette Pearlie K, List Alan F, Padron Eric, Komrokji Rami |
| Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis. Critical reviews in oncology/hematology 2019 Nov 145 102832. Jafari Pourya Arbab, Sadeghian Mohammad Hadi, Miri Hamid Heidarian, Sadeghi Ramin, Bagheri Ramin, Lavasani Sroush, Souri Sae |
| Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern. Blood advances 2019 Oct 3 (20): 3111-3122. Berger Gerbrig, Gerritsen Mylene, Yi Guoqiang, Koorenhof-Scheele Theresia N, Kroeze Leonie I, Stevens-Kroef Marian, Yoshida Kenichi, Shiraishi Yuichi, van den Berg Eva, Schepers Hein, Huls Geert, Mulder André B, Ogawa Seishi, Martens Joost H A, Jansen Joop H, Vellenga E |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: